Systematic literature review and network meta-analysis of oral anticoagulants for the treatment of venous thromboembolism in patients with cancer

(1) Background: Patients with cancer with a hypercoagulable state present an increased incidence of venous thromboembolism (VTE). Neoplastic patients with concurrent VTE undergoing anticoagulant treatment face a series of issues. (2) The aim of the present paper is to systematically summarize current VTE management in patients with neoplasia and to review the current clinical evidence from meta-analyses of randomized controlled trials and guidelines regarding the administration of direct oral anticoagulants (DOACs) for cancer-associated VTE. (3) Search Strategy: We performed a review on meta-analyses of randomized controlled trials and guidelines in favor of the administration of DOACs in patients with cancer-associated VTE published in the last 6 years in the Medline (PubMed) and Embase databases. (4) Results: 21 meta-analyses, 14 randomized controlled studies comparing DOACs to VKAs and LMWH, and 7 national and international guidelines were identified. We identified five studies that show the antineoplastic effect of DOAC on experimental models. (5) Conclusions: DOACs can be seen as the first choice for VTE treatment in neoplastic patients who have a low risk of bleeding, who do not have severe renal impairment, and who are not undergoing treatments that could interact with DOAC’s mechanism of action.

show abstract

“…Hong, Y. [17] 2018 Rivaroxaban was associated with a lower hospital admission rate as compared to LWMH [16].…”

Section: Meta-analysis Publication Year Resultsmentioning

confidence: 99%

Arguments for Using Direct Oral Anticoagulants in Cancer-Related Venous Thromboembolism

et al. 2021

View full text Add to dashboard Cite

show abstract

Systematic literature review and network meta-analysis of oral anticoagulants for the treatment of venous thromboembolism in patients with cancer

Cited by 1 publication

References 0 publications

Arguments for Using Direct Oral Anticoagulants in Cancer-Related Venous Thromboembolism

Arguments for Using Direct Oral Anticoagulants in Cancer-Related Venous Thromboembolism

Contact Info

Product

Resources

About